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ACUTE AND CHRONIC REJECTION: COMPARTMENTALIZATION AND 
KINETICS OF COUNTERBALANCING SIGNALS IN CARDIAC TRANSPLANTS 
ANUPURNA MAHARAJ KRISHEN KAUL 
ABSTRACT 
Heart disease is the major cause of mortality in the United States and other parts of the 
world. Heart transplantation is the treatment of choice for patients with end stage heart 
failure. However, transplanted organs fail due to either acute or chronic rejection. This 
acute and chronic rejection impacts distinct compartments of cardiac allografts. Acute 
rejection is characterized by infiltration of mononuclear cells whereas chronic rejection is 
characterized by progressive narrowing of coronary arteries. In a minor 
histoincompatibility mismatch mouse model we found hearts transplanted from male to 
female C57BL/6 mice undergo an acute rejection with diffuse interstitial infiltrates at 2 
weeks that resolve by 6 weeks when about half of the large arteries develop CAV. These 
processes are dependent on T cells because no infiltrate developed in T cell deficient 
mice. Markers of M1 macrophages were upregulated in the interstitium acutely and then 
decreased as markers of M2 macrophages increased chronically. Interstitial and arterial 
infiltrates were microdissected and expression of an array of 86 genes was screened by 
real time PCR. Programmed cell death protein 1 (PD1), a negative costimulator, and its 
ligand PDL1 were highly upregulated in the interstitium during the resolution of acute 
rejection. Flow cytometry analysis of graft infiltrating cells confirmed an enrichment of 
macrophages expressing PDL1. Treatment with a blocking antibody to PDL1 in the acute 
phase increased interstitial T cell infiltrates. In the arterial compartment, Toll Like 
x 
 
Receptor 4 (TLR4) was upregulated at 6 weeks. Hyaluronan, an endogenous ligand of 
TLR4, was increased in arteries with neointimal expansion. Injection of hyaluronan 
fragments increased intragraft production of chemokines. Our data indicate that negative 
co-stimulatory pathways are critical for the resolution of acute interstitial infiltrates. In 
the arterial compartment recognition of endogenous ligands including hyaluronan by  
innate TLR4 may support the progression of cardiac allograft vasculopathy (CAV). 
Importantly, our model localizes many of the molecular markers that have been 
associated with acute and chronic rejection in clinical studies of cardiac transplants. 
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CHAPTER I 
INTRODUCTION 
 
1.1 Introduction to transplant 
 
 
       1.1.1   Overview and brief history. 
 
 
The history of transplantation is long and complex. The idea of replacing diseased 
or damaged body parts has been around for millennia. Transplants of normal tissues and 
organs have been studied since the early 1900’s.  George Shone in 1912 demonstrated 
that skin grafted between genetically disparate animals (termed “homografts” in that era) 
were rejected.  Moreover, he also demonstrated that subsequent grafts from the same 
donor were rejected more rapidly than the first.  This so-called “second-set” reaction was 
the first evidence of the immune basis of rejection of normal tissues. In 1914, James B. 
Murphy demonstrated that resistance to tumor homografts was dependent on the 
lymphoid system. Also by the end of 1920s, scientists at the Rockefeller Institute 
established other principles of transplantation immunology including the central role of 
the lymphocyte 1. However, widespread appreciation of the immune basis of
2 
 
transplantation was established by the careful observations of Peter Medawar that were 
instigated by the need to perform skin grafts on injured pilots in World War II 2. After the 
war Peter Medawar conducted extensive studies of skin homografts in rabbits, more 
firmly characterizing the timing, histological morphology, and immunological nature of 
rejection. It was Peter Medawar’s experiments that demonstrated induction of chimerism 
can prevent graft rejection. In 1957, Morton Simonsen discovered GVHD (graft versus 
host disease) in chickens that he had injected as embryos with allogeneic lymphoid cells. 
He also demonstrated that to cause GVHD, lymphocytes must be mobile which suggested 
cellular immunity is important 3. Better evidence of cellular immunity was provided by 
Avrion Mitchison. Mitchison introduced the method of passive transfer of cells and 
serum to study transplantation immunity using tumors 4. In 1959, James Gowans gave 
proof of lymphocyte mobility by showing lymphocytes recirculate from blood to lymph 
and back again. Billingham, Brent and Medawar 5, 6 applied passive transfer methods to 
study skin grafts in mice. These passive transfer studies demonstrated that cells from the 
lymph nodes of a transplant recipient could transfer a second-set response to a previously 
“naïve” animal. 
During this same period there were sporadic reports of organ transplants.  With 
the exception of a few autografts of kidneys in dogs, all of these transplants resulted in 
failure.  The first successful kidney transplant in humans was performed between 
genetically identical twin brothers by Murray and colleagues in 1954 7, 8.  Kidney 
transplants between genetically disparate individuals had poor survival until effective 
immunosuppressive drugs were discovered. Joan Main and Richmond Prehn showed that 
weakening the immune system of adult mice by radiation allows them to induce 
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chimerism by inoculating bone marrow cells. Skin grafts were then accepted if they came 
from the bone marrow donor strain 9.  It was not until 1963 when Starzl reported the 
combination of prednisone with azathioprine that clinically acceptable success was 
attained 10. 
With the subsequent introduction of better immunosuppressive drugs, particularly 
cyclosporine in 1980, transplants of liver, hearts and other organs began to have 
successful outcomes 11. 
  In the developed countries the transplantation of human tissue and organ has 
become common. The commonly transplanted vascularized solid organs are: kidney, 
liver, heart and lung. The less frequently transplanted solid organs are pancreas and 
intestine.  More recently composite tissue transplants have been performed.  These 
include arms or hands as well as the highly publicized face transplants. Among non-
vascularized solid organ transplant are heart valve and cornea. Pancreatic islets are 
injected but not surgically grafted. Bone marrow and pluripotent stem cell transplants are 
also transplanted as cell infusions, but because of their immune competence, have the 
additional risk of causing graft versus host disease. The success of a transplant differs 
with the tissue or organ transplanted 12. 
 
1.2  Heart Transplant: 
1.2.1 Overview and brief history: 
 
      Heart transplant is the current therapy for end stage heart failure. The technique for 
heart transplantation was developed at Stanford University by Norman Shumway. The 
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first human heart transplant was performed by Christiaan Barnard in South Africa in 
December 1967. This was followed by a rush of transplants around the world. However, 
the limitation of this procedure was survival rates which were measured in days or weeks. 
This low survival rate was because of rejection and opportunistic infections. The surgical 
technique has changed little. In 1970s the use of endomyocardial biopsy helped clinicians 
to confirm diagnosis of acute allograft rejection. In 1980, cyclosporine was introduced, 
which resulted in improved survivals 13-14.  Advances in immnosuppressive drugs have 
resulted in continued improvements in graft survival. 
 
1.2.2 Statistics/ Survival of heart transplant patients. 
 
There are currently over 2900 people with end stage heart disease waiting for a heart 
transplant in the United States. The median graft survival is approximately 10 years. 
According to the 2013 Registry for the international society for heart and lung 
transplantation (ISHLT) “Acute rejection accounts for no more than 11% of deaths’’ 
because of advances in immunosuppressive drugs which have curtailed the acute 
rejection to a great extent 15. However, chronic rejection, which occurs months to years 
after transplantation, still remains a major challenge for the heart transplant patients. 
The most common indications for cardiac transplantation in the adult are coronary heart 
disease and nonischemic cardiomyopathies. In children cardiomyopathy and congenital 
heart disease are the two most common indications for transplantation 16. 
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1.3.  Overview of cardiac allograft re jection. 
 
Solid organ transplant rejection occurs because of the recipient’s immune response to 
donor tissue 17. At present, success of heart transplantation has mostly been achieved 
through better understanding of the immunology of transplant rejection and the 
application of various strategies for recognizing, treating, and preventing allograft 
rejection 18.   
Cardiac allograft rejection can be classified into three categories: hyperacute, acute and 
chronic rejection 19-20. 
 
1.3.1   Types of allograft rejection 
 
Hyperacute rejection is characterized by thrombotic occlusion of the graft vasculature 
that occurs within few minutes after the transplant. This hyperacute rejection results from 
pre-formed donor specific antibodies (DSA) to ABO blood group antigens or the so 
called major histocompatibility antigens (named HLA in humans for Human Leukocyte 
Antigens) 21. The pathogenesis of hyperacute rejection involves antibody-mediated 
activation of the complement cascade which produces severe damage to the endothelial 
cells, as well as platelet activation followed by coagulation of blood and thrombosis 16. 
Antibodies to HLA are formed generally through pregnancy, blood transfusions or 
previous transplantation 22. Cross-matching involves placing recipient serum potentially 
containing donor-specific HLA antibodies onto donor lymphocytes containing HLA 
antigens. Antibody reactivity can be assessed either by cytotoxic reaction or with 
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fluorescently labeled reagents 23. With the help of blood typing for ABO compatibility 
and cross-matching for antibodies to HLA prior to transplant, hyperacute rejection has 
virtually been eliminated. 
 
Acute Rejection occurs most frequently weeks to months after transplantation and it can 
involve both cell and antibody mediated rejection. Acute rejection is characterized by an 
intense infiltration of T cells and macrophages in the myocardium or antibodies binding 
to microvasculature, that if untreated results in graft loss within days to weeks 24.  
 
Chronic Rejection occurs months to years after transplant and is characterized by the 
progressive narrowing of the coronary artery 25-26. This narrowing of the coronary artery 
is called cardiac allograft vasculopathy (CAV) 24, 26. Chronic rejection results from cell 
mediated or antibody mediated rejection. 
 
1.3.2    Incidence and Pathology of acute cardiac allograft re jection. 
 
The use of immunosuppressive drugs has curtailed acute rejection to a great extent. 
However, still 20% to 50% of patients may experience acute cardiac allograft rejection at 
least once within one year post transplant 27. 
Currently endomyocardial biopsies (EMB) are used as a diagnostic tool for acute cardiac 
allograft rejection 28. Biopsy of myocardium can detect lymphocytic infiltration or 
complement deposition and macrophage infiltration which are characteristic of acute 
cellular or antibody mediated rejection, respectively.  A detailed grading system 
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(International Society of Heart and Lung Transplantation or ISHLT guidelines) is used to 
assess the severity of cellular and antibody mediated rejection and guide treatment 29. 
Based on the grading system that was originally adopted by the ISHLT in 1990, the 
revised 2004 working formulation for the standardization of nomenclature in the 
diagnosis of heart rejection classified acute cardiac allograft rejection into three grades 
(0R to 3R, with 3R being the most severe) (Figure 1A-1R). Briefly, the revised categories 
of cellular rejection are as follows: Grade 0R represents no rejection. Grade 1R represents 
mild rejection, and shows presence of immune cell infiltrates in the interstitial and/or 
perivascular space, with up to 1 focus of myocyte damage. Grade 2R, or moderate 
rejection, is characterized by the presence of two or more foci of cellular infiltrate with 
associated myocyte damage. In grade 3R represents severe rejection which is 
characterized by diffuse cellular infiltrate along with multifocal myocyte damage 
including hemorrhage, edema or vasculitis 29. 
In severe cases like grade 3R there is also participation of granulocytes in the 
rejection process 16. In acute cardiac allograft rejection both donor and recipient-derived 
antigen presenting cells are involved and they can trigger direct and indirect alloresponse, 
respectively. In direct allorecognition, the intact foreign donor MHC antigens and 
peptides presented on the surface of donor APCs are recognized by recipient T cells. The 
donor organ-derived APCs can migrate from the allograft to the recipient’s lymphoid 
tissues, where they activate, through the direct pathway, CD4+ and CD8+ T cells 30-31. 
On the other hand, in indirect allorecognition, the recipient APCs first take up and 
process the donor MHC antigens, before presenting the donor-derived allopeptides to 
recipient T cells. While both direct and indirect pathways are activated as part of the 
8 
 
alloimmune response post-transplant, it is thought that the direct pathway is primarily 
responsible for initiating the acute cellular rejection process, whereas the indirect 
pathway has been linked more so to the development of CAV and chronic rejection 30-31. 
 
 
 
 
Figure 1 (A-F). Grades of cellular Rejection: Hematoxylin-eosin stain on frozen 
section  of (A) showing Grade 0R with intact myocardim with no infiltrates, (B) showing 
Grade 0R  with no infiltrates in interstitium or perivascular space, (C-F) showing Grade 
1R with mild interstitial infiltrates in between myocytes (Tan et al 2007). 
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Figure 1 (G-L). Grades of cellular Rejection: Hematoxylin-eosin stain on frozen 
section of (G-H) showing Grade 1R with focal diffused interstitial infiltrates of 
mononuclear cells, (I-J) showing Grade 1R with focal myocyte damage, (K-L) showing 
grade 2R with mltifocal myocyte damage and intense interstitial infiltrates (Tan et al 
2007). 
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Figure 1 (M-R). Grades of cellular Rejection: Hematoxylin-eosin stain on frozen 
section  of  (M-N) showing Grade 2R with moderate rejection and widening of the 
interstitium, (O-Q) showing Grade 3R  with diffuse inflammation. Myocardial pieces are 
diffusely infiltrated by dense mononuclear inflammatory infiltrates, (R) showing Grade 
3R with edema and hemorrhage with mixed inflammatory infiltrates including neutrophil 
(Tan et al 2007). 
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1.3.3    Incidence and Pathology of Chronic cardiac allograft rejection. 
 
Chronic rejection occurs months to years after transplantation and can also be the 
result of antibody- and cellular-mediated components. Immunosuppression has curtailed 
acute rejection, however chronic rejection still remains a challenge for heart transplant 
patients. Recent estimates indicate that allograft vasculopathy is experienced by 32% of 
patients within five years after transplantation, and by 53% of patients within ten years of 
transplantation 32. The mortality rate among patients with transplant vasculopathy is high, 
and diagnosis of allograft vasculopathy is complicated. Chronic rejection is characterized 
by the progressive concentric narrowing of the coronary artery (Figure 2A-B) along the 
length of coronary vessels 25. This narrowing of coronary artery is called CAV 24, 26. Early 
stages may cause eccentric and focal stenosis that are more obvious in arteries. This loss 
in lumen results from intimal expansion (Figure 3) which occurs due to infiltration of 
host T cells and macrophages and smooth muscle cell proliferation 33-34. CAV is a major 
factor that limits long term survival after cardiac transplantation. 
Examination of endomyocardial biopsies is the current standard for diagnosing 
rejection.   However, it does not detect changes in the coronary arteries which are the site 
of chronic rejection. Therefore, cardiac allograft vasculopathy is detected clinically by 
radiological techniques. There are studies that use more sensitive method of diagnosis 
like intravascular ultrasound (IVUS). IVUS detected new arteriopathy in about half of 
cardiac transplants within one year after transplantation 35. Within 10 years of transplant, 
approximately 90% of patients develop significant CAV 35. 
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Both immune and nonimmune factors contribute to CAV development and impact 
graft survival. Endothelial cells express major histocompatibility complex class I and 
class II antigens, and thus are primary targets of cell-mediated and humoral immune 
responses 16, 36-38. Activated T cells secrete cytokines like tumor necrosis factor, 
interleukins and interferon which promote proliferation of alloreactive T cells that in turn 
activate monocytes and macrophages, and stimulate expression of adhesion molecules by 
endothelial cells 39. After macrophages are activated they are recruited to the intima 
where they release cytokines and growth factors, leading to smooth muscle cell 
proliferation and synthesis of extracellular matrix 40. The humoral immune response 
contributes to CAV through antibody production against HLA and endothelial cell 
antigens. Endothelial cell dysfunction resulting from sustained inflammatory injury also 
predisposes to thrombosis, vasoconstriction, and vascular smooth muscle proliferation 40. 
Nonimmune factors are thought to influence CAV mainly by modulating adaptive 
immune responses 41. Some of the nonimmune factors that are associated with the 
development and progression of CAV include arteritis 42-43, myocardial ischemia, donor-
transmitted coronary atherosclerosis, cytomegalovirus status, deficient fibrinolysis and 
immunosuppressive therapy 26. 
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Figure 2. Schematic representation of a coronary artery, site of CAV (A) H& E staining 
of human heart tissue showing pathology of cardiac allograft vasculopathy (B). 
 
 
 
 
 
Figure 3. Schematic representation of vascular remodeling in CAV depicts mechanisms 
by which vascular remodeling can impact the vessel lumen. Intimal hyperplasia occurs 
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through the recruitment of inflammatory cells and smooth muscle like cells and extension 
of extracellular matrix reduces luminal diameter. Adventitial fibrosis restricts positive 
remodeling of medial smooth muscle cells. Increased medial tone can also participate in 
intimal responses by increasing wall shear stresses (Mitchell et al 2009). 
 
 
1.3.4    Small Animal Models of Cardiac Allografts. 
 
 In small animals, orthotopic cardiac transplantation is not technically feasible. 
Consequently, smaller animal models involve either heterotopic cardiac transplantation or 
vascular grafting. These approaches are complementary models for CAV.   
In our laboratory, we are using heterotopic cardiac transplantation model (Figure 
4). Abdominal heterotopic cardiac transplantation is the gold standard for studying 
cardiac allograft rejection; it is a primarily vascularized model. Graft beating is routinely 
used to assess ongoing graft function. CAV lesions develop within 6–12 weeks and 
accurately replicate most aspects of human disease, including histology and cellular 
composition 44-45. Isografts serve as controls: they do not develop CAV lesions and 
almost no T cells and macrophages infiltrate the graft. This is because isografts have no 
genetic incompatibilities with the recipient and therefore do not elicit an alloimmune 
response. CAV may occur if there is perioperative ischemic injury 46. These isografts are 
used as controls to allograft. 
 
There are certain limitations to the rodent heterotopic transplant model. The first 
and foremost is heterogeneity of CAV severity within a given allograft necessitating 
larger numbers of allografts to obtain meaningful data. Secondly, unlike human coronary 
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arteries that have extensive epicardial segments, the murine coronary circulation is 
predominantly intramyocardial and could be more influenced by mediators present in 
adjacent areas of myocardial rejection. In addition, the rodent coronary diameters are also 
substantially smaller than their human counterparts and have a less well-developed 
media. Also in comparison to human vessels, murine endothelium does not constitutively 
express MHC II and is relatively resistant to neointimal lipid deposition and 
atherosclerosis. 
In an orthotopic location, transplanted hearts have physiologic patterns of 
lymphatic drainage with associated lymph nodes, where antigen presentation and 
lymphocyte activation can occur. Although from heterotopic transplants vascular 
trafficking to the spleen likely occurs, it is unclear where the analogous antigen 
presentation takes place and whether it is comparable to the human situation 26. 
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Figure 4. Schematic describing the heterotopic cardiac transplantation procedure. 
Cardiac allografts are primarily vascularized and beat but are not hemodynamically 
loaded; the host does not rely on the transplant to survive. The donor aorta is 
anastomosed to the host abdominal aorta, and the donor pulmonary vein is sewn to the 
host inferior vena cava. The aortic valve is initially competent and the coronary arteries 
and myocardium are perfused at aortic pressures; blood returns to the right atrium and 
into the host inferior vena cava (Mitchell et al 2009). 
 
 
1.4  Mechanisms controlling cardiac allograft re jection. 
 
1.4.1   Role of Co-stimulatory molecules. 
 
 T cells play an important role in acute and chronic cardiac allograft rejection 47-48. 
Therefore, interfering with T cell activation offers the potential of prolonging graft 
survival through modulation of the alloresponse. The process of T cell activation (Figure 
5) is now recognized to involve multiple signals and distinctly regulated pathways 48. To 
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fully activate naïve T cells, a second signal which is delivered by positive co-stimulatory 
molecules that are present on antigen presenting cells (APCs) is required. These APC’s 
also express negative co-stimulatory molecules that are capable of inhibiting T cell 
activation. Now it is clear that integration of these positive and negative co-stimulatory 
signals by T cells will finally determine the fate and function of the T cell response. The 
best-studied co-stimulatory interactions are those of CD80 and/or CD86 molecules on 
antigen presenting cells (APCs) with CD28 or CTLA-4 on the T-cell surface 49 and CD40 
engagement of its transiently expressed ligand CD154 on the T-cell surface. A positive 
stimulus to T-cell activation results from each of these co-stimulatory interactions, with 
the exception of CTLA-4 ligation by CD80 or CD86, which results in a negative signal. 
Other positive co-stimulatory molecules are ICOS, CD134, CD30, 4-IBB, CD27 and 
CD70 which deliver positive co-stimulation under certain circumstances 50. The negative 
co-stimulatory molecules delivering negative co-stimulation signal are Programmed 
death 1 (PD-1), and CTLA4 50. Mice that are genetically deficient for PD-1 develop 
lymphoproliferative and autoimmune diseases, demonstrating a role in lymphocyte 
deactivation and tolerance 51-52. 
 
PD-1 (CD279) is an inhibitory receptor expressed on activated T, B, and myeloid 
cells 53. PD-1 is a member of the immunoglobulin (Ig) superfamily, shares a 23% identity 
with CTLA-4 and has two ligands with distinct expression patterns: PD-1 Ligand 1 (PD-
L1; B7-H1) and PD-L2 (B7-DC). PD-L1 is expressed on resting T cells, B cells, DCs, 
and macrophages and is further up-regulated upon activation 54, 55. PD-L1 has a tissue 
distribution profile distinct from that of the other B7 family members. PD-L1 has been 
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detected in lymphoid as well as in nonlymphoid organs 56-57, including vascular 
endothelial cells and pancreatic islet cells. In contrast, PD-L2 is inducibly expressed only 
on DCs and macrophages 57. In-vitro studies have shown that engagement of PD1 by its 
ligands inhibits proliferation and cytokine production by antigen-specific CD4+ and 
CD8+ T cells 58.  In-vivo studies have shown that PD-L1 expressed on cardiac 
endothelial cells plays an important role in downregulating a cytotoxic T-cell–mediated 
form of transient myocarditis 59.  
  
 
 
 
 
 
 
 
 
 
 
Figure 5. Schematic representation of Co-stimulatory molecules in T cell activation. 
Activation of T cell requires two signals, first engagement of T cell receptor with MHC 
peptide complex and ligation of co-stimulatory molecules on T cells with their respective 
ligands on antigen presenting cells. T cells receiving both signal 1 and positive co-
stimulation will proliferate and will produce cytokine. However, co-stimulatory 
molecules such as CTLA4 and PD1, can lead to negative T cell signaling resulting in 
reduced cell proliferation and cytokine production (Gao, et al 2003).        
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1.4.2    Role of PD-1 and its ligand PD-L1 in transplantation:  
 
PD-1-PD-L1 interactions control engraftment of solid organ and graft versus host 
disease at several levels 60. PD-1 and PD-L1 both are significantly upregulated on 
alloreactive T cells in transplant recipients 61-62. Sandner et al showed that the 
administration of blocking anti-PD-L1 monoclonal antibody resulted in enhancement of 
alloantigen-driven T cell expansion in-vivo and promoted Th1 differentiation and 
accelerated graft rejection 61. In a model of MHC class II- mismatched (bm12-into-B6 
and B6- into-bm12 models) cardiac allografts it was shown that blocking PD-L1 
expression caused accelerated rejection. This study also indicated that PD-L1 plays an 
important role in regulating CD4+ T-cell mediated alloimmune responses against cardiac 
allografts. In this allograft model, PD-L2 does not play an important role in regulating 
alloimmune response 63. In contrast, administration of a PD-L1-Ig fusion protein that 
triggers PD-1 negative signaling prevents allograft rejection and facilitates tolerance 
induction when combined with anti-CD154 antibody or suboptimal doses of rapamycin 
50. These studies demonstrate the negative regulatory function of the PD-1 pathway in 
organ transplantation. Noritaka et al showed that blockade of the PD-1/ PD-L1 pathway 
upregulated IFN gamma and TNF alpha and enhanced the proliferation of smooth muscle 
cells (SMCs) and CAV 64. In some transplantation tolerance studies it has been shown 
that PD-L1 expression by the endothelium is required to achieve cardiac allograft 
tolerance in a fully allogeneic mismatched model 65. Many other studies demonstrated the 
important role of PD-L1 for induction and maintenance of peripheral transplantation 
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tolerance through its ability to alter the balance between pathogenic and regulatory T 
cells 66. 
 
1.4.3   Cytokine and chemokine expression in cardiac allograft rejection. 
 
Chemokines are a large family of low-molecular-weight (8- to 11-kDa) cytokines 
that mediate cellular trafficking 67. They are expressed by endothelial cells, lymphocytes 
and smooth muscle cells that attract and in turn activate a variety of inflammatory and 
non- inflammatory cells and thus mediate directional migration of immune cells to sites of 
inflammation and injury 68. The chemokine superfamily is divided into 4 subfamilies C, 
CC, CXC, and CX3C based on the presence of a conserved cysteine residue at the amino 
terminus. The C subfamily consists of XCL1 and XCL2, which attract lymphocytes. CC 
chemokines predominantly recruit mononuclear cells 67. The CXC chemokines are 
further distnguished by the presence or absence of the sequence glutamic acid- leucine–
arginine (ELR) near the amino terminal. ELR+CXC chemokines are neutrophil 
chemoattractants with angiogenic properties. ELR-CXC chemokines are chemoattractants 
of lymphocytes with angiostatic properties 69. The fourth subclass of chemokines is 
CX3C subfamily; CX3CL1 is the only known member of this subfamily 67. 
 
The Chemokine actions are mediated by binding to 7-transmembrane spanning G 
protein– coupled receptors (GPCR) 70. These are heterotrimeric G proteins. The 
chemokine receptors undergo internalization and phosphorylation following ligand 
binding. Chemokines can also bind to glycosaminoglycan (GAG) on the cell-surface or 
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within the extracellular matrix. Although this binding does not generate cell signals, it 
maintains stable concentration gradients from the site of chemokine production 71. In 
addition to their trafficking properties, chemokines have also been shown to have several 
extrachemotactic properties, such as cellular activation and differentiation.  
 
1.4.4 Role of chemokines in acute and chronic cardiac allograft re jection. 
                                                                                                                                                                                                          
Multiple clinical studies have shown that donor endothelial cells, T cells, B cells 
and macrophages can all interact with each other and secrete different sets of chemokines 
69. Chemokines contribute to the onset of acute rejection. After transplantation the levels 
of chemokines such as CCL2 (MCP-1), CCL5 (RANTES), CXCL9 (MIG), CXCL10 (IP-
10), CCL3 (MIP-1alpha) and CCL4 (MIP-1beta) increases in cardiac allograft (Figure 6).  
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Figure 6. This plot depicts the expression of chemokines at various stages in immune 
responses to allografts. The early stages are dominated by neutrophils and monocytes, 
followed by NK cells, T lymphocytes, and macrophages, and eventually by smooth 
muscle–like cells and a number of chemokines are expressed such as MIG/CXCL9, 
CCL5 to form GAD lesion in later stage of transplant rejection (Shimizu et al 2003). 
 
 
It has been shown that CCL3, CCL4, and CCL5/RANTES stimulate T-cell 
differentiation into Th-1 subtype. This effect is mediated both directly and indirectly via 
interleukin (IL)-12. In contrast, CCL2/MCP-1 polarizes T- lymphocyte differentiation to 
Th-2 subtype by suppressing IL-12 expression and stimulating IL-4 expression 70. In 
addition, CCL2 also appears to have a direct effect on T- lymphocyte differentiation 
toward Th-2 subtype. Among CXCR3-binding chemokines, CXCL10/IP-10 has been 
shown to enhance generation of tumor-specific T cells and protective immunity in an IL-
12 gene therapy model. CXCL10/IP-10 has also been shown to be important in 
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generation of T- lymphocyte effector function. Another study examined the 
extrachemotactic properties of CXCL9/MIG 70. CXCL9/MIG was shown to stimulate T-
lymphocyte proliferation and increase the number of interferon gamma (IFNg) producing 
T cells both in-vivo and in-vitro. These stimulatory effects are independent of IL-2, but 
are controlled by IFNg, and are found to occur in major histocompatibility complex 
(MHC) class I and II and totally mismatched cardiac transplants. These studies show the 
extrachemotactic properties of some chemokines that is similar to the role of several 
classic cytokines. In transplants these chemokine regulate the recruitment of 
monocyte/macrophages, activated T cells, NK cells and eosinophil and thus contribute to 
the onset of acute rejection 72-73. The infiltrating macrophages have been identified as a 
source of this chemokine 74. It is known that chemokines MCP-1/CCL2, and 
RANTES/CCL5 are the dominant mediators in recruiting monocytes to the rejecting 
organ 75. Studies have demonstrated that blocking of either MCP-1 or RANTES 
substantially reduces intragraft macrophage and T cell accumulation and attenuates 
allograft rejection 76-77. Chemokines also play an important role in cardiac allograft 
vasculopathy. Chemokines can directly contribute to vascular remodeling and 
angiogenesis. The chemokines can contribute to both recruitment and expansion of 
intimal cells in arterial lesions 68. In endomyocardial biopsies increased expression of 
MIG/CXCL9 has been associated with acute rejection 78. 
  
1.4.5 Role of IL1R1 and IL1R2 and their association with cardiac allograft 
re jection: 
 
24 
 
The IL-1 family is comprised of 11 members. These members include IL1alpha, 
IL1beta, IL1 receptor antagonist, IL-18, IL-33 and IL1F5- IL1F-10. IL-1 functions as a 
growth factor for fibroblasts, keratinocytes, lymphocytes, and SMCs and enhances 
activation of B and T cells, many of the cell types implicated in inflammation 79. 
Moreover, IL-1 is an activator of endothelial cell gene expression and is known to 
modulate the presence of cell adhesion molecules such as E-selectin on the endothelial 
surface. These IL1 family members signal through a group of closely related receptors. 
The receptors contain extracellular immunoglobulin domains and a Toll/ IL1 receptor 
(TIR) domain in the cytoplasmic portion 80. IL-1 affects target cells through two distinct 
types of transmembrane receptors that have a nearly identical extracellular domain 81. It is 
known that Interleukin-1 (IL-1) alpha and beta are major proinflammatory cytokines that 
function in immunomodulatory and inflammatory processes, which occur mainly via 
interactions with the IL-1 type I receptor (IL-1RI) 81. IL-1R1 has a 213-amino acid 
cytoplasmic domain that is important for signal transduction. IL-1R1 is found mainly on 
T cells, fibroblasts, keratinocytes, and hepatocytes 82. The IL-1/IL-1RI interaction has 
important effect on cardiovascular events, such as atherosclerosis, myocardial infarction, 
vascular wall remodeling, and the response to vascular injury 83-85. However, IL-1 
activity is tightly regulated by IL-1 receptor type II (IL1R2). IL-1R2 is a non-signaling 
decoy receptor that negatively regulates the activity of IL-1, a pro- inflammatory cytokine 
86. IL-1R2 has a shorter cytoplasmic domain and does not transduce the signal. IL-1R2 is 
found predominantly on B cells, macrophages, and neutrophils 82. In the transplant setting 
it is known that proinflammatory cytokines mediate ischemia-reperfusion injury and 
stimulate immune responses that leads to acute graft rejection. Upregulation of 
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interleukin-1 (IL-1) occurs very early after graft reperfusion 87 as has been demonstrated 
in human heart transplants 88. It has been demonstrated in a rat model that soluble IL-1 
type-2 receptor gene transfer lessens cardiac allograft rejection 82. 
In the Cardiac Allograft Rejection Gene Expression Observational (CARGO) study 11 
genes were validated on RNA extracted from peripheral blood mononuclear cells. This 
gene expression profiling was correlated with findings in endomyocardial biopsies that 
had moderate to severe cardiac allograft rejection. In this study, IL-1R2 was found to 
correlate most strongly with resolution of acute rejection and stable graft function 89-90.   
 
1.4.6 Pattern recognition molecules and their endogenous ligands (Toll like 
receptor, Hyaluronan).  
 
Toll like receptors (TLRs) are a family of pattern recognition proteins that detect 
both microbes and host derived molecular patterns. These pattern recognition proteins are 
expressed on macrophages, dendritic cells and epithelial cells. When ligands bind to 
TLRs, they activate transcription factors that lead to production of inflammatory 
mediators. These TLRs play an important role in the innate immune response and 
subsequently lead to induction of adaptive immune response against pathogens 91. There 
are at least 11 mammalian TLRs that have been identified. Each TLR recognizes distinct 
pathogen associated molecular patterns (PAMPs). Some of the examples of exogenous 
ligands for TLRs are Triacyl lipopeptides, peptidoglycans, dsRNA, LPS, Flagellin and 
unmethylated CpG DNA. In addition to the exogenous ligands, it is known that TLRs are 
receptors for endogenous stimulators that are released from damaged tissues and thus 
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lead to noninfectious inflammatory response 92-93. The endogenous TLR ligands do not 
interact with corresponding receptors in quiescent conditions because of their different 
cellular compartmentalization. But in certain pathological conditions, these endogenous 
molecules are released from injured or necrotic tissues and cells through non-
conventional lysosomal route 94-95. These endogenous molecules activate TLRs and 
initiate a protective inflammatory response and the repair of damaged tissues. For this 
reason endogenous ligands for TLRs are called alarmins and serve as early warning 
signals. As alarmins are released after tissue injury and cell death, they have similar 
response as PAMPs and thus are collectively called as damage associated molecular 
patterns (DAMPs) 96. Some of the examples of endogenous ligands for TLRs are 
hyaluronan 97. HMGB1, CD138, HSP60 and HSP70 98-99. 
. 
 
1.4.7    Hyaluronan  
 
Hyaluronan (HA) is an important structural component of the extra cellular matrix 
(ECM). HA is a glycosaminoglycan polymer composed of repeating disaccharides of beta 
glucuronic acid and N-acetyleglucosamine covalently bound end to end into a simple 
linear glycosaminoglycan 100. HA is synthesized locally in the tissue by various isoforms 
of hyaluronic acid synthase that is present in the plasma membrane of mesenchymal cells 
as high molecular weight polymer, its molecular weight is up to 107 Da 101-102. A local 
degradation of HA occurs in the tissue and it is also cleared through the lymphatics. The 
HA clearance from the blood is extremely rapid and occurs within minutes 101. Even 
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though reticuloendothelial cells in the lymph nodes catabolize a large proportion of 
hyaluroran, some reaches the general circulation. Most of the circulating hyaluronan is 
taken up via receptor mediated endocytosis and degraded by liver sinusoidal endothelial 
cells 103-104. The damage to the sinusoidal endothelial cells, such as from ischemia or drug 
toxicity, is, therefore reflected by an increased serum content of hyaluronan 105.  
 
HA can be broken down into fragments by a number of enzymatic and non-
enzymatic processes 99. Small molecular weight HA has been implicated in several 
biological processes including angiogenesis, cell proliferation, maturation, migration, 
activation of protein tyrosine kinase cascades, and inflammatory gene expression 106. 
These small or low molecular weight HA fragments are increasingly being characterized 
as an endogenous danger signal that promotes the expression of immune mediators. 
Small HA fragments may therefore activate repair processes and signal the immune 
recognition system that injury has occurred 107. Tesara et al showed in murine models that 
these fragments of HA induce DCs to upregulate co-stimulatory molecules CD40 and 
CD86 and produce the proinflammatory cytokine TNF-alpha 108.   
 
  It has been established that the cell surface adhesion molecule CD44 is the 
principal receptor for hyaluronic acid in mouse and human. CD44 has been implicated in 
lymphocyte homing, embryonic development, T cell activation. CD44 is also expressed 
on monocyte/macrophages 109. 
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1.4.8    Hyaluronan Role in transplantation: 
 
Some studies involving solid organ transplants have found an association between 
TLR4 and allograft rejection. One study linked expression of TLR4 activation on the 
cardiac allograft to the development of CAV. In a number of human heart transplant 
recipients, expression of TLR4 and resultant IL-12 and TNF-α production was 
significantly elevated in patients with allograft endothelial dysfunction, which is a 
predictor of subsequent development of CAV 110. McDaniel et al demonstrated that 
increased expression of TLR2 and TLR4 correlated with cardiac allograft rejection 111. 
Johnsson et al showed that during allograft rejection there is local accumulation of 
hyaluronan within the transplanted organ. Accumulation of HA has been seen in cases of 
cardiac, renal and intestinal transplants. The increased tissue content of hyaluronan can 
most probably be attributed to an increased synthesis that is stimulated by cytokine 
released by graft infiltrating immunocompetent cells 112. In murine orthotopic lung 
transplant model it has been demonstrated that accumulation of HA could contribute to 
Bronchiolitis Obliterans Syndrome by directly activating innate immune signaling 
pathways that promote allograft rejection and neutrophilia 113. In one of the study it was 
suggested that fragments of hyaluronan can act as innate immune agonists that activate 
alloimmunity. Using a murine invitro culture it was shown that 135KDa fragment of HA 
induces DC maturation and initiate alloimmunity and this priming of alloimmunity by 
HA activated DCs was dependent on signaling via  TIR associated protein and TLR2 and 
TLR4. Moreover in a murine skin graft model, the same group demonstrated that HA is 
accumulated during skin transplant rejection 108.           
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It has been proposed in the setting of transplantation that both antigen 
independent and dependent mechanisms initiate graft injury leading to production of HA 
fragments (Figure 7) 108. After transplantation the allograft undergoes ischemia 
reperfusion injury allowing the release of fragments of hyaluronan. The hyaluronan 
fragments are recognized by DCs (of either donor or recipient origin) mostly via TLR4 
but with some minor participation of TLR 2.  
 
The TLR signal adaptor TIRAP, which is downstream of TLRs 2 and 4 is 
important for the upregulation of co-stimulatory molecules and the production of 
inflammatory cytokines by fragmented hyaluronan activated DCs. It has been shown that 
TIRAP signaling is important for fHA-activated DCs to prime allogeneic T cells. Primed 
allogeneic T cells then contribute to alloantigen-dependent graft injury. MyD88 is also 
critical for the inflammatory response and Trif participates in this response 108.  
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Figure 7. Schematic representation of TLRs and hyaluronan fragments in allograft 
rejection (Tesar et al 2006). 
 
 
1.5   Compartmentalization of Acute and Chronic Rejection. 
 
Although we know that immune responses to cardiac allografts can result in acute and 
chronic rejection, it is unclear what directs the immune response to localize to different 
compartments of the heart. Acute rejection is characterized by interstitial infiltrates T 
cells and macrophages. However, chronic rejection is characterized by narrowing of the 
coronary arteries. Acute and chronic rejection attack two different compartments of heart. 
The mechanisms underlying this compartmentalization of acute and chronic rejection are 
not known. In this dissertation we will examine the role of different biological molecules 
that are involved in the cardiac allograft rejection.  
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CHAPTER II 
 
ACUTE AND CHRONIC REJECTION: COMPARTMENTALIZATION AND 
KINETICS OF COUNTERBALANCING SIGNALS IN CARDIAC 
TRANSPLANTS 
 
 
 
2.1   Abstract  
 
Acute and chronic rejection impact distinct compartments of cardiac allografts. 
Intramyocardial mononuclear cell infiltrates define acute rejection, whereas chronic 
rejection affects large arteries. Hearts transplanted from male to female C57BL/6 mice 
undergo acute rejection with interstitial infiltrates at 2 weeks that resolve by 6 weeks 
when large arteries develop arteriopathy. These processes are dependent on T cells 
because no infiltrates developed in T cell deficient mice and transfer of CD4 T cells 
restored T cell as well as macrophage infiltrates and ultimately neointima formation. 
Markers of inflammatory macrophages were upregulated in the interstitium acutely and 
decreased as markers of wound healing macrophages increased chronically. Programmed 
cell death protein, a negative co-stimulator, and its ligand PDL1 were upregulated in the
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interstitium during resolution of acute rejection. Blocking PDL1:PD1 interactions in the 
acute phase increased interstitial T cell infiltrates. Toll Like Receptor 4 and its 
endogenous ligand hyaluronan were increased in arteries with neointimal expansion. 
Injection of hyaluronan fragments increased intragraft production of chemokines. Our 
data indicate that negative co-stimulatory pathways are critical for the resolution of acute 
interstitial infiltrates. In the arterial compartment recognition of endogenous ligands 
including hyaluronan by the innate toll like receptors may support the progression of 
arteriopathy. 
 
2.2   Introduction 
 
Immune responses to cardiac allografts can result in acute and chronic rejection. In 
addition to differences in kinetics, acute and chronic rejection attack two different 
compartments of the heart. Acute rejection is defined by interstitial mononuclear cell 
infiltrates with associated myocyte damage as seen in endomyocardial biopsies 1. In 
contrast, chronic rejection primarily involves large coronary arteries. Chronic rejection is 
characterized by diffuse intimal hyperplasia containing mononuclear leukocyte infiltrates. 
Additional mononuclear leukocyte infiltrates are frequently present in the media and 
adventitia 2-4.  This pathological process is diagnosed by angiography or intravascular 
ultrasound and is labeled cardiac allograft vasculopathy (CAV). The incidence of 
interstitial pathology decreases with time after transplantation in most patients, and one 
multicenter study concluded that routine endomyocardial biopsies were not of diagnostic 
value after 5 years except in patients with high risk for acute rejection 5. In contrast, the 
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incidence of CAV increases progressively after transplantation. As a result, advanced 
CAV is often reported with little or no infiltrates in endomyocardial biopsies 2.  
 
Mechanisms underlying compartmentalization of acute and chronic rejection are not 
known. However, the infiltrates in acute and chronic rejection are predominantly 
comprised of T cells and macrophages, which are regulated by many positive and 
negative co-stimulatory signals. The most extensively studied co-stimulatory receptors on 
T cells belong to the CD28 family and include the activating receptor CD28 and 
inhibitory receptor CTLA-4, both of which bind B7-1/CD80 and B7-2/CD86 ligands. 
Another member of the CD28 family is PD1 (CD279), an inhibitory receptor that binds to 
PDL1 and PDL2 (CD274 and CD273) that are expressed on antigen presenting cells 6-8. 
In addition, PDL1 is constitutively expressed by various parenchymal cells including 
cardiomyocytes and can be induced on endothelial cells 6, 9. Therefore, 
compartmentalized pathology could result from differentially expressed ligands for 
positive and negative co-stimulatory receptors on T cells during the process of rejection. 
T cells in turn produce cytokines that direct macrophages to differentiate into performing 
acute inflammatory functions or chronic wound healing functions 10. Clinically, 
macrophages are routinely identified in biopsies by a universal macrophage marker, such 
as CD68 1, 11, 12. Inflammatory macrophages (M1 macrophages) release cytokines 
including IL-1beta and TNFalpha, chemokines such as MIG/CXCL9 and MCP-1/CCL2, 
as well as reactive oxygen species that promote acute interstitial infiltrates 10. Increased 
expression of MIG/CXCL9 in endomyocardial biopsies has been associated with acute 
rejection in clinical studies 13, and infiltrating macrophages have been identified as a 
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source of this chemokine 12. In contrast, wound healing macrophages (M2 macrophages) 
produce growth factors such as TGF beta and VEGF that are elevated in fibrotic 
processes. The balance between inflammatory and wound healing macrophages has not 
been investigated in either acute or chronic rejection of cardiac transplants.  
 
Another set of genes associated with acute rejection was identified in the 
multicentered Cardiac Allograft Rejection Gene Expression Observational (CARGO) 
study. This study was designed to establish gene profiles in peripheral blood 
mononuclear cells that distinguish patients with stable transplants from patients who 
developed acute rejection 14. In the CARGO study, the gene encoding the decoy receptor 
for IL-1 (IL-1R2) correlated most strongly with resolution of acute rejection and stable 
graft function 15, 16. Although IL-1R2 is the predominant receptor for IL-1 on monocytes 
17, the expression of this decoy receptor has not been examined on macrophages in the 
interstitial or arterial compartments of cardiac transplants. 
 
Based on these clinical observations, we hypothesized that differential expression 
of critical molecules in the interstitial and arterial compartments accounts for the distinct 
localization of acute and chronic rejection in cardiac transplants. To test this hypothesis, 
we examined cardiac allografts that were transplanted from male to female C57BL/6 (B6) 
mice. These allografts elicit an  acute rejection that spontaneously resolves and 
progresses to CAV. This enabled us to analyze the pathological process in the interstitial 
and arterial compartments at different stages. Using immunohistology and cell transfers, 
we demonstrated that CD4 T cells are required to orchestrate acute and chronic infiltrates 
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of inflammatory macrophages. An extensive PCR screen of microdissected tissue 
samples revealed sets of genes that were differentially expressed in the interstitial and 
arterial compartments. During acute rejection B7-1/CD80 and B7-2/CD86, which are 
ligands for both positive and negative co-stimulatory receptors on T cells, were more 
highly upregulated in the interstitial than arterial compartment. In addition PDL1/CD274 
was upregulated in the intersititium. The functional relevance of negative co-stimulation 
to the resolution of the acute interstitial infiltrate was tested by treatment with a blocking 
antibody to PDL1. This increased interstitial but not arterial infiltrates of PD1 expressing 
T cells and resulted in acute rejection of cardiac allografts. Acute rejection was 
accompanied by a significant increase in chemokines in the interstitial compartment, 
particularly MIG/CXCL9 that has been found in endomyocardial biopsies from patients 
with findings of acute cellular rejection12, 13. Finally, IL-1R2 was upregulated during 
acute rejection in both the interstitial and arterial compartments and then subsided in 
chronic rejection. These data localize clinically relevant markers in the context of 
pathological findings. 
 
 
2.3   Materials and Methods 
 
 2.3.1  Mice 
 
Male B6 (H2b), Female B6 and Female B6.129S7-Rag1tm1Mom/J (SCID) mice 
were purchased from Jackson Laboratories (Bar Harbor, ME) for use at 8-12 weeks of 
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age. The B6.129S7-Rag1tm1Mom/J (SCID) are homozygous for the Rag1tm1Mom mutation 
and produce no mature T cells or B cells.  These mice have a non-leaky severe combined 
immunodeficiency phenotype. The female C57BL/10NA;-(Tg)TCR Marilyn-(KO) Rag2 
N11, N2 mice (H-2b, Marilyn), age 6 to 8 weeks, were obtained as a generous gift from 
Polly Matzinger (National Institutes of Health, Bethesda, MD) and Olivier Lantz 
(INSERM, Paris, France). All animal studies were approved by the institutional animal 
care and use committee at the Cleveland Clinic Foundation. 
 
2.3.2 Heterotopic heart transplantation 
 
Male C57BL/6 hearts were transplanted into female C57BL/6 or SCID.  
Heterotopic heart transplantation was performed under pentobarbital anesthesia.  The 
donor aorta and pulmonary artery were anastamosed to the recipient’s abdominal aorta 
and inferior vena cava respectively.  Oral Tylenol was used at a dose of 3mg/ml of 
drinking water as an analgesic three days following surgery.  Graft function was 
monitored every week till the end of the experiment.  These animals were sacrificed 
either at 2, 6, 8 or 10 weeks after transplantation. 
 
2.3.3   CD4 T cell isolation, sorting and transfer 
 
CD4 T-cells were isolated from female Marilyn CD4 T-cell receptor transgenic 
mice, in which all T cells are specific for the male minor transplantation antigen 
presented by H-2I-Ab MHC.  Spleens from these transgenic mice were teased into single 
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cell suspensions in PBS + 2% fetal bovine serum.  The red blood cells were lysed using 
ACK lysis buffer (Gibco, Life Tecnologies, Grand Island, NY).  Cells were washed and 
incubated with the following mixture of FITC-labeled antibodies from BD Pharmingen 
(San Jose, CA) for negative selection: CD8a, CD19, CD11c, CD11b, CD117, NK1.1 at 
1:500 dilution.  Labeled cells were removed by flow sorting and the unlabeled CD4 cells 
were transferred to SCID mice 7 days following cardiac transplantation.  These cells were 
>95% CD4+ by flow cytometry.  The time of transfer was designed to avoid the effects 
of nonspecific inflammation from the surgical procedures.   
 
2.3.4    Treatment with blocking antibody or hyaluronan fragments 
 
Recipients were injected intraperitoneally with 3 doses of 200ug of purified 
IgG2a rat monoclonal antibody to PDL1 (clone 10F.9G2) or 200ug of isotype control 
(clone LTF-2) antibody (BioXCell, West Lebanon, NH) on alternate days in the second 
week or sixth week after transplantation.  
Highly purified fragment preparations of hyaluronan (Lifecore Biomedical, LLC) were 
electrophoretically separated as previously described19. A 100ug dose of low molecular 
weight (4.7 or 35kD) hyaluronan was administered intraperitoneally daily from the day of 
transplantation for 2 weeks. Controls were administered equal volumes of the PBS 
diluent. 
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2.3.5    Histology and immunohistochemistry 
 
Full cross-sections through the cardiac grafts were obtained at the time of 
sacrifice and fixed in methanol acetic acid (60% methanol; 10% anhydrous acetic acid; 
30% water). Deparaffinization and antigen retrieval were achieved with 2 incubations in 
Trilogy (Cell Marque, Rocklin, CA) for 30 minutes in a pressure cooker (125C). The 
deparaffinized  slides were cooled, rinsed with water and incubated 20 minutes in 0.3% 
hydrogen peroxide in 80% methanol followed by 10 minutes in Protein Block (Dako, 
Carpinteria, CA). Sections were incubated with primary antibodies diluted with AB 
Diluent (Dako Carpinteria, CA) for 1-2 hours at room temperature. For rabbit primary 
antibodies Super picture polymer detection kit (Invitrogen, Carlsbad, CA) was used, and 
for rat and goat primary antibodies Rat and Goat HRPPolymer (Biocare medical, 
Concord, CA) were used. Staining was visualized with DAB substrate kit for peroxidase 
(Vector Laboratories Inc, Burlingame, CA) before counterstaining with hematoxylin. The 
following primary reagents were used: polyclonal rabbit antibody to CD3 (Abcam, 
Cambridge, MA), rat monoclonal antibody to mouse Galectin-3 (Mac-2; Cedarlane, 
Burlington, 8 NC), rabbit polyclonal antibody to Chitinase 3- like 3 (Ym-1; Stem Cell 
Technologies, Vancouver, Canada), polyclonal goat antibody to PD-1 (R&D systems Inc, 
Minneapolis, MN), rat monoclonal antibody to mouse Foxp3 (eBiosciences, San Diego, 
CA), rabbit polyclonal antibody to Ki67 (Novacastra, Buffalo Grove, IL), rat monoclonal 
antibody to mouse CD44 (Abcam, Cambridge, MA), and biotinylated hyaluronic acid 
binding protein (Millipore, Billerica, MA). 
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     2.3.6    Laser capture microdissection and real time RT PCR  
 
      Frozen sections on PET-Membrane slides (Leica, Buffalo Grove, IL) stained with 
Arcturus Histogen solution (Life Technologies, Grand Island, NY) were microdissected 
on a Leica AS-LMD microscope. Samples were collected in RNAlater. Total RNA was 
isolated using the RNeasy micro kit and reverse transcribed with the RT2 PreAMP cDNA 
synthesis kit (QIAGEN, Gaithersburg, MD). Expressions of 86 genes (Table 1) was 
screened with a customized PCR array kit (QIAGEN). Eighteen genes were analysed in 
additional samples by qPCR using the ddCT method 21, calibrated to (control sample) and 
normalized to B-actin. TaqMan assay numbers for all genes measeured are listed in 
(Table 2).  
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Table 1. Complete list of genes on microarray. 
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Table 2. PCR primer sequences. 
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2.3.7    Isolation of graft infiltrating cells for flow cytometry 
 
Cells infiltrating the graft were isolated as previously described 18. Briefly, grafts 
were removed after perfusing the recipient with RPMI media to flush cells from the 
circulation. The apical half of the graft was weighed and incubated 1 h at 37C in RPMI 
with Type II collagenase (Sigma- Aldrich) before pressing through a 40 μm filter. The 
collected cells were washed twice in RPMI, counted and stained for phenotypic surface 
markers (CD45, CD4, CD11b, F4/80, PDL1, PD1 and IL1-R2 from BD Bioscience, San 
Jose, CA; eBioscience, San Diego, CA, USA). Flow cytometry was performed using a 
FACSCalibur (BD Biosciences) cytometer and FlowJo analysis software (Tree Star Inc., 
Ashland, OR, USA). The forward scatter and FL1 (CD45+) channels were used to gate 
on leukocytes followed by analysis of the specific leukocyte populations. For each 
sample, 2x105 events were accumulated. 
 
2.3.8    Quantitation of chemokines, hyaluronan and IL-1 receptors in allografts 
 
Grafts were removed and homogenized in 500ul of proteinase inhibitor. Then 1 
ml of 1.5% Triton X-100 in PBS was added before shaking 30 minutes at 4C. After 
pelleting cell debris, the supernatants were collected and total protein concentration 
quantified by Coomassie Plus Protein Assay Reagent kit (Pierce, Thermo Fisher 
Scientific, Rockford, IL). Protein concentrations were determined using ELISA kits for 
CXCL9, CCL5, CCL2 and hyaluronan from R&D Systems (Minneapolis MN), and IL-
1R1 and IL-1R2 from US Biological (Marblehead MA). 
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2.3.9    Analysis of gene expression by quantitative RT-PCR 
 
Total RNA was isolated from interstitium and arterial compartment using RNeasy 
micro kit (Qiagen, Gaithersburg, MD) followed by cDNA preparation using RT2 
PreAMP cDNA synthesis kit (QIAGEN, Gaithersburg, MD).  PCR was performed with 
FAM dyelabeled probes (Applied Biosystems, Grand Island, NY) for mouse cd274 
(PDL1), TLR2, TLR4, Actb and Mrpl32 (gene assay ID nos. Mm00452054_m1, 
Mm00442346_ml, Mm00445273_ml, Mm00607939_Sh and Mm00777741sH, 
respectively).  The expression level of the housekeeping gene is subtracted from the 
expression level for each test gene.  These gene expression levels were compared to the 
isograft controls. 
  
2.3.10     Statistical Analysis 
 
Statistical analyses were performed using GraphPad Prism 5.0 software 
(GraphPad Software Inc. San Diego, CA). Differences between groups for cell numbers 
and chemokine content were evaluated using an unpaired Student’s t-test. 
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2.4. Results: 
 
2.4.1 Hearts transplanted from male to female B6 undergo acute re jection that 
transitions into chronic re jection. 
 
Female recipients of male B6 hearts were sacrificed 2 or 6 weeks after 
transplantation to assess acute and chronic manifestations of rejection. At 2 weeks, 
allografts contained diffuse interstitial infiltrates of T cells and macrophages with limited 
periadventitial involvement of larger arteries (Figure 8A,B). By 6 weeks interstitial 
infiltrates diminished, and about half of the large arteries developed adventitial and 
intimal mononuclear infiltrates predominantly composed of macrophages (Figure 8C,D). 
Isograft controls did not exhibit pathological changes (Figure 9A- D).  
 
Most macrophages in the acute and chronic lesions were intensely positive for 
Galectin-3, a marker of activated macrophages that contribute to cardiovascular disease 
22, 23. These macrophages were elongated with cytoplasmic projections and frequently 
formed clusters (Figure 8B inset). Few macrophages in either the acute or chronic 
infiltrates were positive for Ym-1, a marker for M2 macrophages 10. Moreover, these M2 
macrophages were scattered as individual large ovoid cells (Figure 10A,B). We also 
45 
 
found limited numbers of Foxp3 positive regulatory T cells in interstitial and arterial 
compartments (Figure 10C,D). 
 
 
 
Figure 8.  Immunoperoxidase stains of acute and chronic infiltrates in cardiac allografts. 
At 2 weeks (top row), allografts contained a diffuse interstitial infiltration of CD3 T cells 
(A) and Galectin-3+ macrophages (B) with limited periadventitial involvement of larger 
arteries (right side of figures). The macrophages displayed cytoplasmic projections on 
high power (inset). At 6 weeks, the interstitial infiltrates diminished, and large arteries 
developed adventitial and intimal infiltrates composed of CD3 T cells (C) and larger 
numbers of macrophages (D).  Original magnifications 200x (inset 600x). 
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Figure 9. Immunoperoxidase stains of mononuclear infiltrates in cardiac isograft at 2 and 
6 weeks in wild type recipients. At 2 weeks (top row), male cardiac isografts to wild type 
male recipients contained few CD3 T cells (A) and Galectin-3 positive macrophages (B) 
with no pathology. At 6 weeks (second row), the  male cardiac isografts to wild type male 
recipients contained few CD3 T cells (C) and Galectin-3 positive macrophages (D) with 
no pathology. Original magnifications 200x. 
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Figure 10. Only limited numbers of macrophages in either the 2 week (A) or 6 week (B) 
infiltrates were positive for Ym-1 (Chitinase 3-like 3) a marker for M2 macrophages. 
These M2 macrophages were scattered as individual large ovoid cells (inset). Limited 
numbers of Foxp3 positive regulatory T cells were present both in interstitial and arterial 
compartments at 2 weeks (C) and 6 weeks (D).  
 
 
2.4.2 CD4 T-cells orchestrate acute and chronic rejection 
 
Because H-Y peptides are presented in the context of MHC class II molecules, we 
tested the requirement for CD4 T cells in generating acute and chronic pathology. Hearts 
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were transplanted from wild type male B6 mice into female B6 Rag1 deficient recipients 
(B6.RAG-/-), which lack mature T and B cells. One week later we reconstituted the 
recipients with 2-3x104 CD4 T cells from transgenic female B6 mice that express T cell 
receptors for H-Y peptides in the context of H2-IAb (Marilyn mice). Female B6.RAG-/- 
recipients were sacrificed at 2 and 6 weeks after cell transfer. Two control groups were 
used: Isografted hearts from female B6 mice into female B6.RAG-/- recipients, which 
were reconstituted with 2x104 CD4 T cells from Marilyn transgenic mice, and allografted 
hearts from male B6 mice into female B6.RAG-/- recipients, which were not 
reconstituted. In the absence of T cell reconstitution, no infiltrates developed in the male 
B6 cardiac allografts to female B6.RAG-/- recipients (Figure 11A, B). Similarly, CD4 T 
cells from Marilyn mice did not cause infiltrates in isografts to female B6.RAG-/- 
recipients at either 2 (Figure 11C, D) or 6 (Figure 11E, 4F) weeks. However, CD4 T cells 
from Marilyn mice reconstituted acute interstitial infiltrates that progressed to CAV in 
male B6 cardiac allografts to female B6.RAG-/- recipients. As in wild type recipients, 
both acute and chronic infiltrates were composed of T cells and macrophages, but 
activated macrophages predominated (Figure 12A-D). An additional group of mice 
sacrificed at 10 weeks had more extensive arterial lesions in their allografts, but the T 
cells had diminished (Figure 12E), and macrophages increased (Figure 12F). At this time, 
the neointima had progressed to contain alpha-smooth muscle expressing cells (Figure 
13). 
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Figure 11.  Immunoperoxidase stains of mononuclear infiltrates of CD3 (A) and 
Macrophages (B) in cardiac allograft at 2 weeks in Rag1-/- recipients with male wild type 
heart.  Female wild type heart transplanted to female RAG-/- recipients reconstituted with 
Marilyn CD4 T cells, contained few CD3 T cells (C) and Galectin-3 positive 
macrophages (D) at 2 weeks. At 6 weeks, no arteries developed vaculopathy and only 
few CD3 T cells (E) and few Galectin-3 positive macrophages (F).  Original 
magnifications 200x. 
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Figure 12.  Male hearts transplanted to female RAG-/- recipients reconstituted with 
Marilyn CD4 T cells. At 2 weeks, allografts contained diffuse interstitial infiltrates of 
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CD3 T cells (A) and Galectin-3+ macrophages (B) with limited periadventitial 
involvement of larger arteries. At 6 weeks, the interstitial infiltrates diminished, and large 
arteries developed adventitial and intimal infiltrates of CD3 T cells (C) and large 
numbers of macrophages (D). At 10 weeks, the arterial lesions contained decreased 
numbers of CD3 T cells (E), and increased macrophages (F).  Original magnifications 
200x (A-D) and 40x (E, F). 
 
 
 
 
 
Figure 13.  Male hearts transplanted to female RAG-/- recipients reconstituted with 
Marilyn CD4 T cells and sacrificed at 10 weeks. Large artery with limited numbers of T 
cells (A), large numbers of macrophages in the neointima as well as adventitia (B), and 
alpha-smooth muscle expressing cells in the neointima (C).  Original magnifications 
200x. 
 
 
2.4.3   Mediators expressed more highly in the interstitial than in the arterial 
compartments during acute and chronic rejection 
 
Laser capture microdissection was used to isolate tissue from the interstitial and 
arterial compartments of allografts and isografts (Figure 14). Real Time PCR array 
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analysis was performed on tissue captured from the two compartments to evaluate the 
expression of 86 different genes in a single plate. Table 3 lists the most highly 
upregulated genes in the interstitium of allografts compared to isografts at 2 and 6 weeks. 
These included the chemokines MIG (CXCL9), RANTES (CCL5) and MCP-1 (CCL2); 
the co-stimulatory molecules B7-1/ CD80, B7-2/ CD86, and PDL1 (CD274); IL-1 
receptors (IL1R1 and IL1R2); the Toll like Receptors TLR2 and TLR4. The chemokine 
genes were more highly upregulated at 2 weeks than at 6 weeks in the interstitium of 
allografts compared to isografts. In contrast, TLR2 and 4 increased with time after 
transplantation. 
 
Because MIG and MCP-1 are produced by M1 inflammatory macrophages, 
additional microdissections were performed and the captured tissues were probed for 6 
markers for M1 macrophages (IL-1beta, IL-6, IL-15, IL-18, TNFalpha and Nos2), all of 
which were increased more in the interstitium than in the arterial compartment at 2 weeks 
(Figure 15B). By 6 weeks, all of the M1 markers had decreased in the interstitium and 
increased in the arterial compartment. Changes in MIG and MCP-1 were congruent with 
the M1 markers in these samples (Figure 15A).  The converse was found for five markers 
for M2 macrophages (Ym1, Fizz1, VEGF, TGFbeta, and CD206), which were more 
elevated in the arterial compartment than in the interstitum at 2 weeks (Figure 15C).  By 
6 weeks, these M2 markers had decreased in the arterial compartment and increased in 
the interstitium. The exception to this pattern was IL-10, which was most elevated 
acutely in the interstitium, but was elevated in at 2 and 6 weeks in both compartments 
(Figure 15C). 
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Chemokine expression was confirmed on the protein level by ELISA on tissue 
homogenates of allografts. These homogenates were prepared from the apex of the heart 
that contains myocardium but no large arteries, and therefore, sampled the interstitial 
compartment. MIG, RANTES and MCP-1 were all elevated at 2 weeks and diminished 
by 6 weeks in parallel with interstitial infiltrates (Figure 16A).  
 
 
 
Figure 14.  Procurement of individual vascular  compartments laser capture 
microdissection method allowed for the separate dissection of the mouse interstitium and 
coronary arteries. 
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Table 3. Genes upregulated in microdissected allografts expressed as fold change 
compared to isograft. 
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Figure 15.  Quatitative PCR on 3 microdissected allografts at 2 and 6 weeks expressed as 
fold change relative to isografts from the same time points. Confirmation of  key 
cytokines, receptors and ligands from the initial PCR array (A).  Markers for M1 
inflammatory macrophages are consistently higher in the interstium (left panel) at 2 
weeks (filled bars) than at 6 weeks (open bars), whereas in the arterial compartment 
(right panel) these markers are low at 2 weeks and increase by 6 weeks (B).  In contrast, 
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the converse occurs for markers of M2 wound healing macrophages with the exception of 
IL-10 (C).  Error bars represent standard errors of the mean of 3 allografts. Differences 
between 2 and 6 week values were significant at the P<0.05*; <0.01**; or <0.001*** 
level as indicated. 
 
 
 
Figure 16A. Confirmation of expression of chemokines by ELISA.  MIG, RANTES and 
MCP-1 were elevated at 2 weeks and then diminished by 6 weeks in the homogenates of 
myocardium from cardiac allografts (A).   
 
 
2.4.4    Expression of IL-1R2 and PDL1 by cells in the circulation and infiltrating 
grafts 
 
Because of the potential importance of the decoy receptor for IL-1 and negative 
co-stimulatory signals for T cells in resolving the acute interstitial infiltrates, we 
investigated the expression of IL-1R2 and PDL1 in more detail. IL-1R2 protein was 
elevated in the graft homogenates at 2 weeks by ELISA (Figure 16B). 
  The increase in PDL1 in interstitial compared to arterial tissue at 2 weeks and 6 
weeks was confirmed by qPCR analysis (Figure 16G). Flow cytometry on cells isolated 
from the allografts at 2 weeks demonstrated that about 25-30% of CD45 labeled cells 
were F4/80+ macrophages, and PDL1 was expressed by almost 80% of these 
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macrophages (Figure 16C). This represented a major enrichment compared to the low 
percentage of circulating monocytes that expressed PDL1 (16±0.6%; Figure 16D). Local 
expansion may contribute to the enrichment of PDL1 expressing macrophages in the graft 
because many of the macrophages labeled with the proliferation marker Ki67 in the 
interstitial and arterial compartments (Fig 16E, 16F). 
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Figure 16 (B-G). Confirmation of expression of the decoy receptor for IL-1 and negative 
co-stimulatory ligand PDL1 by ELISA and flow cytometry.  IL-1R2 was also elevated in 
the allograft compared to isograft homogenates at 2 weeks and to a lesser degree at 6 
weeks by ELISA (B). Flow cytometry demonstrated that PDL1 was expressed by 
majority the F4/80+ macrophages that were infiltrating the allografts at 2 weeks (C).  This 
represented a major enrichment compared to the limited percentage of circulating 
monocytes that expressed PDL1 (D). Local expansion may contribute to the enrichment 
of PDL1 expressing macrophages in the graft because many of the macrophages labeled 
with the proliferation marker Ki67 at 2 weeks (E) and 6 weeks (F).  Each symbol in the 
scattergams represents data from an individual animal. Levels of CD274 (PDL1) mRNA 
in interstitial compared to arterial tissue in allografts at 2 weeks and 6 weeks as measured 
by qPCR (G).  
 
 
 
2.4.5    Blocking PDL1 early prevents resolution of acute interstitial infiltrates 
 
The effects of blocking the negative signals delivered by PDL1 on acute 
interstitial infiltrates was tested by treating female B6 recipients of male cardiac 
allografts with monoclonal antibody to PDL1 or isotype control antibody on days 8, 10 
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and 12. By 15 days, 50% of animals treated with antibodies to PDL1 had completely 
rejected their allografts while no grafts were rejected in the control group (Table 4). The 
grafts were removed at this time for evaluation. Blockade of PDL1 caused a greater than 
two-fold increase in interstitial infiltrates of CD3+ T cells and PD1expressing cells 
compared to the control group (Figure 17A-E), but  did not increase arterial pathology. 
Double staining demonstrated that many cells co-expressed CD3 and PD1; single positive 
CD3 and PD1 cells were also detected (Figure 18).  
 
To determine whether blockade of PDL1 would modulate chronic arterial 
pathology, we delayed treatment with antibody to PDL1 to days 34, 36 and 38. All the 
allografts continued functioning in recipients treated either with antibody to PDL1 or 
isotype controls and sacrificed at 6 weeks after transplantation. Blocking PDL1 caused 
about a 2 fold increase in number of CD3 and PD1 cells in the interstitium compared to 
control treated group, but the absolute numbers of cells was almost 50% lower than at 2 
weeks after transplantation (Figure 17E,F). Treatment with PDL1 antibody at this later 
period after transplantation did not increase vascular pathology. 
 
 
 
 
 
 
60 
 
Table 4.  Cardiac allograft survival after treatment with blocking antibodies to 
PDL1. 
 
 
* Recipients were injected intraperitoneally with 3 doses of 200ug of purified IgG2a rat 
monoclonal antibody to PDL1 (clone 10F.9G2) or 200ug of isotype control (clone LTF-
2) antibody (BioXCell, West Lebanon, NH) on days 8, 10 and 12 and sacrificed on day 
15. 
 
** Recipients were injected intraperitoneally with 3 doses of 200ug of purified IgG2a rat 
monoclonal antibody to PDL1 (clone 10F.9G2) or 200ug of isotype control (clone LTF-
2) antibody (BioXCell, West Lebanon, NH) on days 34, 36 and 38 and sacrificed on day 
42. 
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Figure 17.  Immunohistology and cell counts from mice treated with blocking antibodies 
to PDL1.  Administering blocking antibody to PDL1 on days 8, 10 and 12 increased 
interstitial infiltrates of CD3+ T cells (B) and PD1+ (D) cells compared to controls (A and 
C, respectively) at 2 weeks. Blocking PDL1 did not increase arterial pathology at 2 weeks 
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(right side of panels A-D).  Cell counts per 5 high power fields verified about a 2-fold 
increase in CD3 and PD1 expressing cells at 2 weeks (E) and 6 weeks (F), but there was 
an overall decrease in cells from 2 to 6 weeks.  Each symbol in the scattergrams 
represents an individual animal.  All differences between control and anti-PDL-1 treated 
mice were significant <0.05. 
 
 
 
 
 
 
Figure 18.  Immunohistology of acute interstitial infiltrates in allograft following 
treatment with blocking antibodies to PDL1. Double stain for CD3 (brown) and PD1 
(blue) demonstrates the majority of cells express both CD3 and PD1 (original 
magnification 600x). 
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2.4.6 Effect of blocking PDL1 early on mediators in the interstitial and arterial 
compartments  
 
Allografts to recipients treated with blocking antibody to PDL1 and control 
recipients were microdissected for PCR analysis to determine changes associated with 
accelerated rejection. Blocking PDL1:PD1 interactions caused an additional increase in 
MIG, RANTES, MCP-1 and IL-1R1 as well as IL-1beta, IL-6, TNFalpha and Nos2 in the 
interstitium, but not in the arterial compartment at 2 weeks (Figure 19B,C).  M2 
macrophage markers were increased to a lesser extent (Figure 19D). 
The chemokine expression was confirmed on the protein level by ELISA on homogenates 
of control and experimental allografts. All three chemokines were upregulated by 
treatment with antibodies to PDL1 (Figure 19A). However, these chemokines were more 
highly expressed at 2 weeks than at 6 weeks.  
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Figure 19.  Treatment with blocking antibodies to PDL1 resulted in increased expression 
of MIG, RANTES and MCP-1 in allografts by ELISA that was greater at 2 weeks than 6 
weeks (A).  These samples were taken from the apex of the hearts which contains few 
large arteries. Microdissection of allografts at 2 weeks demonstrated levels of MIG, 
RANTES, MCP-1, IL-1R1, IL-1beta, IL-6 TNFa and Nos2 were greater in the 
interstitium than the arterial compartment (B, C).  M2 macrophage markers were changed 
to a lesser extent (D).  Bars represent average of 3-4 samples in each group. PCR results 
represent fold changes compared to allografts treated with control antibody.  Differences 
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between interstitial and arterial values were significant at the P<0.05*; <0.01**; or 
<0.001*** level as indicated. 
 
 
 
 
2.4.7 TLR4 and hyaluronan are upregulated in the arterial compartment during 
chronic rejection 
 
PCR array analysis showed IL1R2 and TLR4 were the most upregulated genes in 
the microdissected arterial compartment in allografts compared to isografts at 2 weeks. 
By 6 weeks, IL1R2 had decreased and TLR4 had dramatically increased (Table 3). This 
was confirmed by qPCR analysis (Figure 20).  
Among the endogenous ligands reported for TLR4 is fragmented hyaluronan, an 
extracellular matrix component that is known to be upregulated in various forms of 
arterial injury. Increased amounts of hyaluronan were detected by ELISA in homogenates 
of allografts at 2 and 6 weeks compared to isografts (Figure 21A). Immunohistology 
demonstrated increased hyaluronan in the interstitium at 2 weeks and in the neointimal 
lesions and surrounding adventitial infiltrates of arteries as well as the interstitium of 
cardiac allografts at 6 weeks (Figure 21B). Immunofloresence  on allograft artery showed 
HA expression (Figure 22A) compared to non specific control (Figure 22B). In isografts, 
hyaluronan was present as a compact band in the adventitia (Figure 21C). CD44, which is 
the dominant receptor for hyaluronan, was expressed by the cells infiltrating the 
neointima and adventitia (Figure 23). 
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Figure 20.  TLR4 quantification by qPCR analysis on interstital and arterial tissue from 
allografts relative to isografts at 2 and 6 weeks. 
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Figure 21.  Upregulation of hyaluronan in the arterial compartment at 6 weeks.  ELISA 
measurements of hyaluronan in allografts and isografts (A). Differences at 6 weeks were 
significant P<0.01. Hyaluronan surrounded infiltrating mononuclear cells in the 
neointimal lesions and adventitia of arteries as well as the interstitium of the graft  (B). In 
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isografts, hyaluronan formed a compact band in the adventitia of large and smaller 
arteries with limited amounts in the interstitum (C).  Original magnifications 200x. 
 
 
 
 
 
Figure 22. Immunofloresence showing HA expression in allograft artery (A) and non 
specific control (B). 
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Figure 23. CD44, which is the dominant receptor for hyaluronan, was expressed by the 
cells infiltrating the neointima and adventitia of the wild type artery (A) and SCID artery 
with passive transfer of transgenic CD4 T cells (B) at 6 weeks. 
 
 
2.4.8    Low molecular weight hyaluronan increases MIG and MCP-1 production 
in cardiac allografts 
 
Inflammation can cause fragmentation of hyaluronan and different sized 
fragments of hyaluronan can promote or modulate chemokine production. Circulating 
hyaluronan fragments have been found to stimulate chemokine production by 
macrophages through a TLR4- and TLR2-dependent mechanism 24. To test whether 
hyaluronan fragments increased MIG and MCP- 1 in cardiac allografts, we administered 
100ug of low molecular weight hyaluronan daily to female recipients of male allografts 
intraperitoneally. Controls were administered an equal volume of the PBS diluent. Both 
4.7 or 35kD fragments of hyaluronan stimulated MIG and MCP-1 production in the 
cardiac allografts by 2 weeks (Figure 24A). Infiltrating cells were isolated from cardiac 
transplants to mice treated with PBS or 35kD fragments of hyaluronan, and after cell 
sorting for F4/80 expressing macrophages, mRNA was isolated and markers of M1 and 
M2 macrophages were probed by PCR.  In addition to MIG and MCP-1, the M1 markers 
IL-6, IL-15, IL-18, TNFa and Nos2 were increased (Figure 24B-D). 
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Figure 24.  Both 4.7 or 35kD fragments of hyaluronan stimulated MIG (top left) and 
MCP-1 (top right) measure by ELISA on homgenates from the apex of cardiac allografts 
at 2 weeks (A).  PCR on macrophages isolated from 3 heart allografts at  2 weeks 
demonstrated increased expression of MIG and MCP-1 as well as even greater increases 
in IL-6, IL-15, IL-18 TNF and Nos2 (B,C). Markers for M2 macrophages were 
changed to a lesser extent (C).  Each symbol in the ELISA scattergram represents results 
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from an individual allograft.  PCR results are expressed as fold increase in macrophages 
from mice treated with hyaluronan fragments compared to PBS (n=3).  
 
 
 
2.5.    Discussion 
 
This study was designed to discover mediators that differentially modulate acute 
mononuclear infiltrates in the myocardium and chronic infiltrates in the large arteries. As 
in human cardiac transplants, the infiltrates in acute and chronic rejection were 
predominantly composed of mononuclear cells with macrophages outnumbering T cells 1, 
11. However, the acute and chronic pathology were dependent on T cells because no 
infiltrates developed in the absence of T cells, and passive transfer of CD4 T cells 
restored not only the characteristic T cell infiltrates, but also the extensive macrophage 
infiltrates and ultimately neointima formation with smooth muscle cells.  
 
         Macrophages are identified routinely in clinical endomyocardial biopsy by 
universal macrophage markers, such as CD68 1, 11, 12. Subpopulations of macrophages are 
now recognized to have critical functional differences 10. The most clearly defined types 
of macrophages are classically activated or inflammatory M1 macrophages and 
alternatively activated or wound healing M2 macrophages. Sustained production of IFNg 
by T helper 1 (Th1) cells induces inflammatory macrophages during adaptive immune 
responses; whereas wound healing macrophages develop in response to production of IL-
4 by T helper 2 (Th2) cells. No clinical or experimental studies have assessed 
macrophage subpopulations in cardiac allografts, but Famulski et al 25 have reported that 
M2 macrophages increase with time during T cell-mediated rejection in mouse renal 
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allografts. We found relatively few Ym-1 expressing M2 macrophages in the acute 
interstitial infiltrates and they increased modestly with time. Moreover, the M2 
macrophages were largely ovoid without cytoplamic extensions. These histological 
findings were supported by 5 molecular markers of M2 macrophages (Ym1, Fizz1, 
VEGF, TGFb, and CD206), which were expressed at low levels in the interstitium and 
increased at 6 weeks. 
 
         In contrast, six markers of M1 macrophages (IL-1b, IL-6, IL-15, IL-18, TNFa and 
Nos2) were markedly elevated in the interstitium at 2 weeks and decreased by 6 weeks.   
These changes in M1 markers paralleled the numbers and morphology of  galectin-3 
expressing macrophages, which had many cytoplasmic extensions that made contact with 
endothelial cells and myocytes. In hearts, galectin-3 has been associated with fibrosis 22. 
Furthermore, MIG, a signature cytokine produced by inflammatory macrophages, was 
elevated in interstitial samples by microarray and ELISA. MIG has been reported to co-
localize with infiltrating CD68+ macrophages in clinical endomyocardial biopsies during 
acute cellular rejection 12.  
 
        In the transition to chronic rejection, galectin-3-expressing macrophages and MIG 
decreased in the interstitium, and increased in the arterial compartment. In vitro, galectin-
3 stimulates human macrophages to upregulate inflammatory genes including RANTES 
and MCP-1 23. These 2 chemokines were upregulated acutely in the macrophage-rich 
interstitium and chronically in the arterial compartment.  
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        In addition to increased expression of chemoattractants for macrophages and T cells, 
ligands for both positive and negative co-stimulatory receptors on T cells were 
upregulated in the intersititum. While CD80 and CD86 can stimulate T cells through 
CD28, PDL1 delivers a negative signal to T cells that express PD1. The majority of T 
cells in the interstitium expressed PD1 on immunohistology. The functional relevance of 
the interaction between PDL1 and PD1 was demonstrated by treating mice with a 
blocking antibody to PDL1. Blocking PDL1:PD1 interaction has been reported to 
increase acute and chronic rejection of cardiac allografts in other murine models 
depending upon the histoincompatibility and treatment schedule 9, 26-28. In our model, 
treatment in the acute phase caused a doubling of the number of PD1 positive cells in the 
interstitium and resulted in increased tissue injury. Blocking PDL1 in the chronic phase 
also increased the number of PD1 positive cells in the interstitium, but to a lesser extent 
than in the acute phase. Increased infiltrates of macrophages and T cells were 
accompanied by increased MIG and RANTES production in the interstitium. Yang et al 
29 reported that blocking PDL1 decreased FoxP3 expressing T regulatory cells in the 
spleen, but not in cardiac allografts. We also found only limited numbers of FoxP3 cells 
in the interstitium or arterial compartment of cardiac allografts. Of note, blocking PDL1 
changed the balance of IL-1 receptors. At 2 weeks IL-1R2 predominated in untreated 
mice, but blocking PDL1 resulted in the upregulation of IL-1R1. IL-1R2 is structurally 
similar to IL-1R1, but has a truncated cytoplasmic domain that prevents transmembrane 
signaling 17. IL-1R2 competes with IL-1R1 for ligands and for the IL-1 receptor 
accessory protein. By acting as a decoy receptor for IL-1 on macrophages, IL-1R2 
modulates the inflammatory effects of IL-1. The counterbalance between IL-1R2 and 
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PD1 in our model parallels the clinical findings in the multicenter CARGO study of gene 
profiles in peripheral blood mononuclear cells, which reported that IL-1R2 was the gene 
most highly correlated with stable graft function and PD1 with acute rejection of cardiac 
transplants 15, 16. Our examination of graft infiltrates by flow cytometry indicated that 
macrophages were equipped to modulate acute rejection because the majority expressed 
PDL1.  
 
         By microdissecting tissue sections from cardiac allografts rather than homogenizing 
entire samples, we examined the compartmentalization of mediators and ligands. On 
microarray screen, only IL-1R2, TLR2 and 4 were more highly expressed in the arterial 
than interstitial compartment in the acute phase. By 6 weeks, TLR4 increased in both 
compartments, but more in arteries. TLR4 has several endogenous ligands that are 
upregulated in injured arteries including galectin-3 and hyaluronan 30, 31. The extracellular 
matrix macromolecule hyaluronan has been found to increase in the hyperplastic intima 
of restenotic arteries 32. Macrophages engage in extracellular matrix remodeling both 
degrading and synthesizing hyaluronan 33. Changes in distribution of hyaluronan are not 
studied routinely in clinical cardiac transplants, but have been implicated in rejection of 
human lung transplants 34, 35. Hyaluronan levels are also increased in male skin 2 weeks 
after allotransplantation to female recipients 35. Similarly, in our model, hyaluronan was 
increased in homogenates of cardiac transplants at 2 and 6 weeks. In addition, we 
demonstrated that increased amounts of hyaluronan were localized in the neointima of 
arteries in cardiac allografts, which contained activated macrophages that could 
contribute to fragmentation of the hyaluronan. Circulating hyaluronan fragments 
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stimulate chemokine production by macrophages through a TLR4- and TLR2-dependent 
mechanism 24. In our model the administration of low molecular weight hyaluronan 
fragments stimulated MIG and MCP-1 expression as well as M1 markers in macrophages 
isolated from allografted hearts.  
 
              In summary, we found a differential expression of inflammatory signals in the 
interstitial and arterial compartments of cardiac transplants that changed from the acute to 
chronic phases of rejection. Our data indicate that upregulation of PDL1 in the 
interstitium contributes to the resolution of acute interstitial infiltrates.  In the arterial 
compartment recognition of endogenous ligands including hyaluronan by TLR4 may 
promote progression of arteriopathy. Importantly, our model localizes molecular markers 
that have been associated with acute and chronic rejection in clinical studies of cardiac 
transplants. 
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CHAPTER III 
 
CONCLUSION AND FUTURE WORK 
 
Cardiac allograft vasculopathy (CAV) 1-2 continues to be the major cause of chronic graft 
failure while advances in the treatment strategies for cardiac transplant patients have 
controlled acute rejection to a large extent. The studies presented in this thesis were 
designed to examine the mechanisms that are involved in the compartmentalization of 
acute (localized in interstitium) and chronic (localized in large arteries) rejection. Our 
results in cardiac allografts between mice mismatched at a minor histoincompatability 
showed that infiltrates in acute and chronic rejection were composed of macrophages and 
T cells 3,4. These results were similar to human cardiac transplants.  Using 
immunodeficient mice, we were able to show that both the acute and chronic pathology 
was dependent on CD4 T-cells because no infiltrates developed in the absence of T cells, 
and passive transfer of CD4 T-cells restored not only the characteristic T cell infiltrates, 
but also the extensive macrophage infiltrates. Even in human cardiac transplants, CD4 T-
cells have been shown to be a major component of acute and chronic infiltrates 5.  
However, these experiments did not answer why acute infiltrates were more intense in the 
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interstitium than in arteries. It is known that endothelial cells activated by T cell–derived 
cytokines and macrophages express class II MHC, adhesion molecules, and co-
stimulatory molecules. These can present antigen and thereby recruit more T cells, 
amplifying the rejection process. It has also been reported that activated capillary 
endothelial cells express more message for leukocyte adhesion molecules than arterial 
endothelial cells 6. This greater expression of adhesion ligands by capillary endothelial 
cells together with the slower blood flow in the narrow lumen of the vessels permits low 
affinity interactions of lectin- like adhesion glycoproteins, called the selectins to 
effectively mediate leukocyte rolling.  Leukocyte rolling precedes the firm adhesion and 
subsequent transendothelial migration of leukocytes mediated by the interaction of 
integrins (CD11/CD18, VLA-4) on leukocytes with immunoglobulin- like adhesion 
molecules on ECs (e.g., ICAM-1, VCAM-1).  The importance of adhesion molecules on 
capillary endothelium to early interstitial T cell infiltrates has been shown with cardiac 
allografts from ICAM-1 deficient donors.  Fewer T cells infiltrate these grafts at 4 days, 
but these grafts still develop chronic CAV 7. 
 
                   In contrast to acute rejection, CAV is caused by infiltrates expanding in the 
arterial compartment over time.  The transfer of CD4 T cells to immunodeficient 
recipients of cardiac grafts demonstrated that CD4 T cells caused the chronic arterial 
pathology as well as the acute interstitial infiltrates.  Moreover, the numbers of 
macrophages increased in these arterial lesions from 6 weeks to 10 weeks. The 
proliferation marker Ki67 showed that many of the cells in the graft had recently divided. 
This marker does not indicate whether the cells underwent mitosis in the arterial lesion or 
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had proliferated in the lymphoid tissues and then migrated to the graft because the Ki-67 
protein is present during all active phases of the cell cycle (G(1), S, G(2), and mitosis), 
but is absent from resting cells (G(0))8. However, the exact location where proliferation 
was initiated remains unclear, more specifically whether cells proliferated in the graft or 
in the spleen. This could be tested by performing splenectomy at different times after 
transplantation.  Additionally, FTY720 (fingolimod) could be used to inhibit lymphocyte 
release from secondary lymphoid tissues 9 
 
                        T-cells can produce cytokines that direct macrophages to differentiate into 
M1 inflammatory macrophages or M2 wound healing macrophages 10. Macrophages are 
differentiated into M1 phenotype by INFg and M2 phenotype by IL-4. These M1/M2-
type macrophages necessarily direct T cells towards Th1- or Th2- like activities, 
respectively. Macrophages initiate and direct virtually all immune responses 11 (Figure 
25).  
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Figure 25. Schematic showing macrophages initiate and direct virtually all immune 
responses (Mill’s et al, 2014). 
 
 
 
Our PCR and ELISA results on tissue homogenates of graft show upregulation of 
chemokines, MIG (CXCL9), RANTES (CCL5) and MCP-1 (CCL2) that are involved in 
the graft rejection. Manipulations of chemokines, MIG, RANTES and MCP-1 or their 
receptors in the system can further elucidate the mechanisms involved in the activation, 
co-stimulation, and interactions between inflammatory cells.  Multiple strategies such as 
using antibodies to block chemokines and their receptors or using knockout animals to 
block cellular interactions could be used for future studies. MIG, RANTES and MCP-1 
are interferone gamma inducible chemokines. Other possible targets indicated by our 
PCR results include IL-1β that could be addressed by treatment with the soluble form of 
the IL-1 decoy receptor IL-1R2 as discussed below.  
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                         T-cells are regulated by many positive and negative co-stimulatory 
signals. Our results exhibit upregulation of PD-L1, a ligand for PD-1 which is a negative 
co-stimulatory molecule in the interstitium. We demonstrated functional relevance of 
negative co-stimulation to the resolution of the acute interstitial infiltrate by treating mice 
with a blocking antibody to PD-L1. These results indicated that early blocking of PD-L1 
prevents resolution of acute interstitial infiltrates. However, it did not modulate chronic 
arterial pathology. Blocking PD-L1:PD-1 interaction not only caused an additional 
increase in chemokine level, IL-1R1, IL-1beta, IL-6, TNF alpha and Nos2 in the 
interstitium at 2 weeks but also changed the balance of  IL-1 receptors. At 2 weeks, IL-
1R2 predominated in untreated mice, but blocking PDL1 resulted in the upregulation of 
IL-1R1. In our model, the counterbalance between IL-1R2 and PD1 parallels the clinical 
findings in the multicenter CARGO study of gene profile that reported IL-1R2 is the most 
highly correlated gene with the stable graft function and PD1 with acute rejection of 
cardiac transplants 12, 13. The results on graft infiltrates by flowcytometry in this work, 
show that macrophages were able to modulate acute rejection because the majority 
expressed IL-1R2 and PDL1. Manipulations in the IL-1 receptors in the system can 
further clarify if resolution of acute interstitial infiltrate in anti PD-L1 treated group is 
dependent on IL1R1.  
                
                   Toll like receptors (TLRs) are a family of pattern recognition proteins that 
detect both microbe and host derived molecular patterns. In our study TLR2 was 
increased in the arterial more than in the interstitial compartment of cardiac allografts in 
the acute phase. However, TLR4 and hyaluronan were upregulated in the arterial 
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compartment during chronic rejection. Hyaluronan is one of the endogenous ligands for 
TLR2 and TLR4 14. In our model, hyaluronan was increased in tissue homogenates of 
cardiac allografts at 2 and 6 weeks. This increased amount of hyaluronan was localized in 
the neointimal lesions and surrounding adventitial infiltrates of arteries in cardiac 
allografts. Additionally, administration of low molecular weight hyaluronan increased 
MIG and MCP-1 production in cardiac allografts.  We attempted to address this question 
by transplanting hearts from male TLR4 knockout donors into female recipients.  
However, this produced an unexpected phenotype of a dilated myocarditis 15.  
Alternatively, de la Motte and others have shown that intermediate sized fragments of 
HA can deliver anti- inflammatory signals 16.  Therefore, the effects of different sizes of 
HA fragments could be assessed as inhibitors of CAV. 
                     
The results presented in this thesis were obtained in a mouse model. It would be 
important to translate these findings in human specimens.  This is important because of 
the anatomical and physiological differences between mouse and human coronary 
arteries.  Only a short segment of the mouse coronary is epicardial; then majority is 
intramyocardial. In contrast the major branches of human coronaries that develop CAV 
remain on the epicardial surface surrounded by adipose tissue. Moreover, the large 
epicardial coronary arteries of humans are nourished by vasa vasorum.  The absence of 
vasa vasorum in the intramyocardial coronary arteries is one factor that is thought to offer 
them relative protection from arteriosclerosis. The application of the panel of probes used 
in the mouse model to samples from human transplants would verify markers that are 
common to the development of CAV. 
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Figure 26. Schematic representation of Acute Balance of Immunity between 
Compartments  
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Figure 27. Schematic representation of Chronic Balance of Immunity between 
Compartments 
 
                  The studies presented in this thesis show differential expression of 
inflammatory signals in the interstitial and arterial compartments of cardiac transplants 
that changed from acute to chronic phases of rejection (see Figures 26 and 27). Negative 
co-stimulatory pathways are critical for the resolution of acute interstitial infiltrates. In 
the arterial compartment recognition of endogenous ligands including hyaluronan by the 
innate TLR4 may cause cardiac allograft vasculopathy to progress. The findings from 
these and future experimental studies will further our understandings and treatments for 
human cardiac allograft rejection. 
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                   To conclude, our results show that there is acute (Figure 26) and chronic 
(Figure 27) balance of immunity between interstitial and arterial compartments.   
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APPENDIX 
 
In continuation with chapter II, we have additional findings on transfer of different 
numbers of Marilyn CD4 T-cells to female B6 SCID recipient of male B6 heart grafts. 
These results show that the reconstitution of B6 SCID recipients of heart transplants with 
CD4+ cells from Marilyn mice is dose dependent in the spleen and blood. Additionally, 
the acute production of chemokines (MIG, RANTES, IP-10, MCP-1 and INFG) in the 
graft caused by transferring CD4+ Marilyn T Cells is both dose and time dependent. 
 
Hearts transplanted from male to immunodeficient female B6 reconstituted with 
Marliyn CD4 T cells is dose and time dependent in both blood and spleen 
 
Hearts were transplanted from wild type male B6 mice into female B6 Rag1 deficient 
recipients (B6.RAG-/-), which lack mature T and B cells. One week later we 
reconstituted the recipients with 5x104, 2x104, 2x103, 1x103 CD4 T cells from transgenic 
female B6 mice that express T-cell receptors for H-Y peptides in the context of H2-IAb 
(Marilyn mice). Female B6.RAG-/- recipients were sacrificed at days 6, 7-8, 15, 16 and 4 
weeks after cell transfer. The flow-cytometry results showed that reconstitution with 
Marilyn CD4 T cells is dose and time dependent in blood and spleen (Figure 1).  
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Figure 1. Flowcytometry analysis showing percentage of CD4 T-cells in blood and 
spleen of immunodeficient recipient at different time points. 
 
Percentage of CD4 T cells in Blood and Spleen is definitively time dependent. 
 
Male hearts which were transplanted into female B6 Rag1 recipient reconstituted with 
2x104 Marilyn CD4 T cells and sacrificed at 1, 4 and 6 weeks. The results from 
flowcytometry showed that percentage of CD4 T-cells decreasing with time for a 
constant dosage (Figure 2A-B). Even the splenic weight of these mice decreased with 
time. These results correlated with the histology data from cardiac allografts, (refer 
chapter-II), depicting intense infiltration of cells at early time point that further decreases 
with time. 
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Figure 2.  Flowcytometry analysis showing percentage of CD4 T cells in Blood (A) 
and Spleen (B). The splenic weight (C) shows the same trend with time. 
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Acute production of chemokines in the graft caused by transferring CD4+ Marilyn 
T cells is time dependent. 
 
Chemokine expression was quantitatively evaluated at protein level by ELISA on tissue 
homogenates of male hearts which were transplanted into female B6 Rag1 recipient 
reconstituted with 2x104 Marilyn CD4 T cells and sacrificed at 1, 4 and 6 weeks. MIG, 
RANTES, MCP-1, IP-10 and INFg decreased with time with constant dosage (Figure 2). 
These homogenates were prepared from the apex of the heart that contains myocardium 
but no large arteries, and therefore, sampled the interstitial compartment. However, 
isograft control at 1 and 6 week did not show any chemokine production. 
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Figure 3. Chemokine MIG (A) RANTES (B) MCP-1 (C) IP-10 (D) & IFNg (E) 
expression in cardiac allografts were quantified using ELISA on tissue homogenates of 
allografts and isografts graft at 1wk ,4 wk and 6wks  
 
 
